Bio-Bridge Science to Present at the Rodman & Renshaw 8th Annual Healthcare Conference
November 02 2006 - 12:19PM
Business Wire
Bio-Bridge Science, Inc. (OTCBB:BGES) a developer of vaccines with
broad preventative and therapeutic applications, is pleased to
announce that the Company will be presenting at the 2006 Rodman
& Renshaw 8th Annual Healthcare Conference
(www.rodmanandrenshaw.com/us06conference), November 6-8. The
presentation, to be given by Dr. Liang Qiao, the Company's Chairman
and CEO, is scheduled for Wednesday, November 8 at 10:35 AM (ET) in
the Kennedy II room on the 4th floor of the New York Palace Hotel.
Dr. Liang Qiao will provide a company overview as well as in-depth
information on the unique technology platform exclusively licensed
to the Company. About Bio-Bridge Science: Bio-Bridge Science
(http://www.bio-bridge-science.com/) is a biotechnology firm
focused on the development of vaccines with broad therapeutic and
preventive applications. Bio-Bridge is developing a promising new
HIV Vaccine that is expected to enter clinical trials in the near
future in China. The vaccine, based on exclusive technology
co-developed by CEO Dr. Liang Qiao, an associate professor at
Loyola University Chicago's Strich School of Medicine, targets
infection in mucosal tissues, which is a unique approach to prevent
and treat HIV infection. Bio-Bridge Science's GMP facility will
also be used to develop vaccines against cervical cancer and colon
cancer under the same technology platform. The company plans to
develop these vaccines in the United States and Japan in the
future. Forward Looking Statements: This press release contains
forward-looking statements as defined by the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements concerning plans, objectives, goals, strategies, future
events or performance, and underlying assumptions and other
statements that are other than statements of historical facts.
These statements are subject to uncertainties and risks including,
but not limited to, product and service demand and acceptance,
changes in technology, economic conditions, the impact of
competition and pricing, government regulation, and other risks
defined in this document and in statements filed from time to time
with the Securities and Exchange Commission. All such
forward-looking statements, whether written or oral, and whether
made by or on behalf of the company, are expressly qualified by
these cautionary statements and any other cautionary statements
which may accompany the forward-looking statements. In addition,
the company disclaims any obligation to update any forward-looking
statements to reflect events or circumstances after the date
hereof. Please refer to SEC filings for additional information.
Bio-Bridge Science, Inc. (OTCBB:BGES) a developer of vaccines with
broad preventative and therapeutic applications, is pleased to
announce that the Company will be presenting at the 2006 Rodman
& Renshaw 8th Annual Healthcare Conference
(www.rodmanandrenshaw.com/us06conference), November 6-8. The
presentation, to be given by Dr. Liang Qiao, the Company's Chairman
and CEO, is scheduled for Wednesday, November 8 at 10:35 AM (ET) in
the Kennedy II room on the 4th floor of the New York Palace Hotel.
Dr. Liang Qiao will provide a company overview as well as in-depth
information on the unique technology platform exclusively licensed
to the Company. About Bio-Bridge Science: Bio-Bridge Science
(http://www.bio-bridge-science.com/) is a biotechnology firm
focused on the development of vaccines with broad therapeutic and
preventive applications. Bio-Bridge is developing a promising new
HIV Vaccine that is expected to enter clinical trials in the near
future in China. The vaccine, based on exclusive technology
co-developed by CEO Dr. Liang Qiao, an associate professor at
Loyola University Chicago's Strich School of Medicine, targets
infection in mucosal tissues, which is a unique approach to prevent
and treat HIV infection. Bio-Bridge Science's GMP facility will
also be used to develop vaccines against cervical cancer and colon
cancer under the same technology platform. The company plans to
develop these vaccines in the United States and Japan in the
future. Forward Looking Statements: This press release contains
forward-looking statements as defined by the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements concerning plans, objectives, goals, strategies, future
events or performance, and underlying assumptions and other
statements that are other than statements of historical facts.
These statements are subject to uncertainties and risks including,
but not limited to, product and service demand and acceptance,
changes in technology, economic conditions, the impact of
competition and pricing, government regulation, and other risks
defined in this document and in statements filed from time to time
with the Securities and Exchange Commission. All such
forward-looking statements, whether written or oral, and whether
made by or on behalf of the company, are expressly qualified by
these cautionary statements and any other cautionary statements
which may accompany the forward-looking statements. In addition,
the company disclaims any obligation to update any forward-looking
statements to reflect events or circumstances after the date
hereof. Please refer to SEC filings for additional information.
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jul 2023 to Jul 2024